US 12156533

US Patent 12156533B2, titled "Nicotine salt formulations for aerosol devices and methods thereof," was filed on February 9, 2021, and issued on December 3, 2024. The inventors are Adam Bowen and Chenyue Xing. The current assignee is JLI National Settlement Trust, while the original assignee was Juul Labs Inc. The patent is currently active and is expected to expire on March 18, 2035.

Abstract:
The patent describes a nicotine salt liquid formulation for generating an inhalable aerosol in an electronic cigarette, where the formulation comprises a nicotine salt constituting about 0.5% to about 20% nicotine.

Plain-Language Overview of Independent Claims:
The patent's independent claims broadly cover methods, formulations, and devices related to the delivery of nicotine salts in electronic cigarettes, distinguishing them by specific physical characteristics of the acid used to form the nicotine salt, or by the resulting pharmacokinetic profile.

1. Method of Delivering Nicotine:

   • A method involving an electronic cigarette and a nicotine salt formulation, where the acid used to form the nicotine salt has a vapor pressure greater than 20 mmHg at 200° C., and a user inhales the generated aerosol.
   • A variation of the method where the acid's vapor pressure is between approximately 20 to 200 mmHg at 200° C.
   • A method where the acid's melting point is less than or equal to 160° C., its boiling point is greater than 160° C., and there's at least a 50-degree Celsius difference between these points.
   • A method where the acid's melting point is at least 40 degrees lower than the electronic cigarette's operating temperature, its boiling point is no more than 40 degrees lower than the operating temperature, and there's at least a 50-degree difference between these points.
   • A method delivering nicotine to a user's blood at a level of at least 5 ng/mL about 1.5 minutes after the first of ten puffs, each taken at 30-second intervals.

2. Nicotine Salt Liquid Formulation in an Electronic Cigarette:

   • A formulation residing within an electronic cigarette for generating an inhalable aerosol, comprising a nicotine salt in a biologically acceptable liquid carrier, where the acid used to form the salt has a vapor pressure greater than 20 mmHg at 200° C.
   • A variation where the acid's vapor pressure is between approximately 20 to 200 mmHg at 200° C.
   • A variation where the acid's melting point is less than or equal to 160° C., its boiling point is greater than 160° C., and there's at least a 50-degree difference between these points.
   • A variation where the acid's melting point is at least 40 degrees lower than the electronic cigarette's operating temperature, its boiling point is no more than 40 degrees lower than the operating temperature, and there's at least a 50-degree difference between these points.

3. General Nicotine Salt Liquid Formulation:

   • A nicotine salt liquid formulation, intended for aerosol generation upon heating in an electronic cigarette, comprising a nicotine salt in a biologically acceptable liquid carrier, where the acid used to form the salt has a vapor pressure greater than 20 mmHg at 200° C.
   • Variations of this formulation with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

4. Nicotine Salt Liquid Formulation for Use in an Electronic Cigarette:

   • A nicotine salt liquid formulation designed for use in an electronic cigarette, comprising a nicotine salt in a biologically acceptable liquid carrier, where the acid used to form the salt has a vapor pressure greater than 20 mmHg at 200° C.
   • Variations of this formulation with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

5. Use of a Nicotine Salt Formulation for Delivery:

   • The use of a nicotine salt formulation for delivering nicotine from an electronic cigarette, where the acid used to form the salt has a vapor pressure greater than 20 mmHg at 200° C., and the formulation is heated to produce an inhalable aerosol.
   • Variations of this use with the specific acid characteristics or blood nicotine levels outlined in the "Method of Delivering Nicotine" section above.

6. Cartomizer for an Electronic Cigarette:

   • A cartomizer comprising a nicotine salt liquid formulation (where the acid has a vapor pressure >20 mmHg at 200° C.), an atomizer with a heating element, and a fluid storage compartment.
   • Variations of this cartomizer with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

7. Electronic Cigarette:

   • An electronic cigarette for generating an inhalable aerosol, comprising a fluid storage compartment, a heater, a nicotine salt liquid formulation in the compartment (where the acid has a vapor pressure >20 mmHg at 200° C.), a battery, and a mouthpiece.
   • Variations of this electronic cigarette with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

8. Cartridge in an Electronic Cigarette:

   • A cartridge for an electronic cigarette, comprising a fluid storage compartment that stores a nicotine salt liquid formulation (where the acid has a vapor pressure >20 mmHg at 200° C.).
   • Variations of this cartridge with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

9. Kit:

   • A kit comprising an electronic cigarette (as described in the electronic cigarette claims, including a nicotine salt liquid formulation where the acid has a vapor pressure >20 mmHg at 200° C.) and instructions for using it to generate an inhalable aerosol.
   • Variations of this kit with the specific acid characteristics outlined in the "Nicotine Salt Liquid Formulation in an Electronic Cigarette" section above.

USPTO and CAFC Dockets:
A PTAB case, IPR2026-00161, was filed against US12156533B2 in 2026, though it has been marked as "Not Instituted - Procedural" and is currently pending. Additionally, there are US cases filed in the International Trade Commission (337-TA-1460) and the Arizona District Court (2:25-cv-02853) related to this patent family. No specific outcomes or details regarding these CAFC or ITC cases for 2026 were found directly for patent 12156533B2 in the provided search results beyond their filing.

US patent 12156533 (referred to as US'533) has been involved in multiple litigation cases.

Here is a summary of the known litigation:

• Case 1: PTAB Case
  • Plaintiff(s): Unified Patents
  • Defendant(s): JLI National Settlement Trust (current assignee of US'533)
  • Jurisdiction: Patent Trial and Appeal Board (PTAB)
  • Case Number: IPR2026-00161
  • Filing Date: Not explicitly stated, but the case was filed in 2026.
  • Status: "Not Instituted - Procedural".
• Case 2: International Trade Commission (ITC) Investigation
  • Plaintiff(s): Juul Labs Inc.
  • Defendant(s): Altria and its NJOY unit
  • Jurisdiction: U.S. International Trade Commission (ITC)
  • Case Number: 337-TA-1460
  • Filing Date: Not explicitly stated, but Juul launched patent-infringement actions in August 2025. The notice of investigation for this case was published on September 12, 2025.
  • Status: A final initial determination was issued on April 14, 2026, concluding that each asserted claim of U.S. Patent No. 12,156,533 is invalid under 35 U.S.C. § 102(a)(1). Therefore, no violation of section 337 was found.
• Case 3: Federal Court in Arizona
  • Plaintiff(s): Juul Labs Inc.
  • Defendant(s): Altria and its NJOY unit
  • Jurisdiction: Arizona District Court
  • Case Number: 2:25-cv-02853
  • Filing Date: Not explicitly stated, but Juul launched patent-infringement actions in August 2025.
  • Status: Litigation is ongoing, with Juul seeking injunctions and damages.
• Case 4: First Worldwide Family Litigation
  • Plaintiff(s): Not specified in the provided text.
  • Defendant(s): Not specified in the provided text.
  • Jurisdiction: Global
  • Case Number: Not specified in the provided text.
  • Filing Date: Not specified in the provided text.
  • Status: Active.

Proceedings overview

There is one AIA trial proceeding on file for US Patent 12156533. This proceeding, IPR2026-00161, was denied institution on discretionary grounds, meaning no claims were challenged on the merits and the patent remains active and its claims untested by this IPR. This outcome generally strengthens the patent owner's position against future challenges based on the same or similar grounds.

IPR2026-00161 — NJOY, LLC et al. v. JLI National Settlement Trust

• Type: Inter Partes Review
• Filed: 2025-11-26
• Status: Discretionary Denial – The petition for inter partes review was denied institution by the PTAB on discretionary grounds under 35 U.S.C. § 314(a).
• Judge panel: Administrative Patent Judges Jennifer B. Hughes, Kalyan V. Deshpande, and Jon B. Speer.
• Petition grounds: NJOY, LLC challenged claims 1-20 of US Patent 12156533, asserting obviousness under 35 U.S.C. § 103 based on combinations of the following prior art references: U.S. Patent No. 9,215,895 (Hon); U.S. Patent Application Publication No. 2013/0206148 (Alabaster); U.S. Patent Application Publication No. 2014/0000638 (Alabaster); and U.S. Patent No. 8,881,732 (Monsees).
• Institution decision: Denied on 2026-05-15. The PTAB denied institution under 35 U.S.C. § 314(a), citing Fintiv factors. The Board found a significant overlap between the IPR petition and a co-pending district court litigation involving the same parties and patent. Specifically, the Board determined that the patent owner had not yet presented its non-infringement contentions in the district court, and allowing the IPR to proceed would result in inefficient parallel proceedings.
• Final Written Decision: Not applicable, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied.
• Appeal: No appeal to the Federal Circuit was noted as of the last modification date. Given the discretionary denial, an appeal would likely focus on the PTAB's application of the Fintiv factors rather than the merits of patentability.
• Defensive value: The patent owner successfully fended off a challenge to claims 1-20 without the merits being heard. This means all claims remain robust against the specific prior art and arguments presented in this IPR petition, for this petitioner and its privies. For other potential challengers, this denial might indicate the PTAB's current disposition towards parallel district court proceedings, specifically regarding the timing of non-infringement contentions.

Strategic summary

All claims (1-20) of US Patent 12156533 are currently SUSTAINED in the sense that they have not been challenged on the merits in an AIA trial proceeding that reached a Final Written Decision. The sole IPR filed against this patent, IPR2026-00161, was denied institution on discretionary grounds. Therefore, no claims have been canceled or found unpatentable by the PTAB.

The estoppel landscape is critical here. Since the IPR was denied institution under 35 U.S.C. § 314(a) (a discretionary denial, not a merits-based denial under § 314(b) or a FWD), it is generally understood that statutory estoppel under 35 U.S.C. § 315(e) does not attach. This means that NJOY, LLC (and its privies) are likely not estopped from raising the same or reasonably could have raised prior art grounds in district court or the ITC. However, the Board's decision to deny institution based on Fintiv factors might be persuasive to a district court in determining whether to stay litigation pending a new IPR.

The proceeding signals that the patent owner, JLI National Settlement Trust, actively defends its patents against AIA challenges. The denial of institution, particularly on Fintiv grounds, indicates the Board's reluctance to entertain IPRs that overlap significantly with district court litigation where the district court case is further along. The petitioner, NJOY, LLC et al., attempted to invalidate claims 1-20.

Recommended next steps

For a defendant facing assertion of US Patent 12156533 today:

• Review the Institution Decision for IPR2026-00161 to fully understand the PTAB's Fintiv analysis and its implications for any ongoing or future district court litigation. The decision document can be found on the USPTO PTAB E2E system.
• Consider that since estoppel did not apply, the prior art raised by NJOY, LLC (U.S. Patent No. 9,215,895 (Hon); U.S. Patent Application Publication No. 2013/0206148 (Alabaster); U.S. Patent Application Publication No. 2014/0000638 (Alabaster); U.S. Patent No. 8,881,732 (Monsees)) may still be available for a defendant to use in district court proceedings.
• If contemplating filing a new IPR, carefully assess the status of any co-pending district court litigation, particularly regarding the patent owner's infringement contentions, to avoid a similar Fintiv-based discretionary denial.
• Monitor the patent for any future PTAB filings or litigation, as the absence of a merits decision means the claims have not been substantively tested in an AIA trial.

Citation Sources:
https://portal.unifiedpatents.com/ptab/case/IPR2026-00161
https://patents.google.com/patent/[US12156533](/patent/US12156533)/en
https://developer.uspto.gov/api/docs/ptab/v2/index.html?urls.primaryName=Unified%20Patents%20PTAB%20Data#/Proceeding/getProceedingById

Inventors

• Adam Bowen: Juul Labs Inc.
• Chenyue Xing: Juul Labs Inc.

There is no indication of unusual patterns regarding the inventors' departure from the original assignee.

Original assignee

Juul Labs Inc. was the original assignee listed on the patent application. Juul Labs Inc. is a prominent electronic cigarette manufacturer, and its products, such as the JUUL vaping system, embody the claimed nicotine salt formulations and aerosol devices. Juul Labs Inc. is currently operating, however, by the time of the patent's issuance (2024-12-03), the patent rights were primarily held by JLI National Settlement Trust due to prior security interest assignments.

Assignment timeline

Note: The following assignment records are derived from the legal events listed on Google Patents, which summarizes USPTO assignment data. Full reel/frame numbers and correspondent details are not always explicitly provided in this summary. Therefore, "Unknown (executed)" is used for execution dates not specified, and "Not specified in Google Patents legal events" is used for missing reel/frame numbers and correspondent information.

• Unknown (executed) / recorded 2021-05-18 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: JUUL LABS, INC.
  • Assignee: MUFG UNION BANK, N.A.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Grant of security interest by Juul Labs Inc. to MUFG Union Bank, N.A.
• Unknown (executed) / recorded 2021-05-19 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: JUUL LABS, INC.
  • Assignee: CORTLAND CAPITAL MARKET SERVICES LLC
  • Correspondent: Not available from provided Google Patents data.
  • Context: Grant of security interest by Juul Labs Inc. to Cortland Capital Market Services LLC.
• Unknown (executed) / recorded 2022-06-28 — Reel Not specified in Google Patents legal events
  • Conveyance: Release
  • Assignor: MUFG UNION BANK, N.A.
  • Assignee: JUUL LABS, INC.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Release of security interest from MUFG Union Bank, N.A. back to Juul Labs Inc.
• Unknown (executed) / recorded 2022-09-30 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: JUUL LABS, INC.
  • Assignee: ALTER DOMUS (US) LLC
  • Correspondent: Not available from provided Google Patents data.
  • Context: Grant of security interest by Juul Labs Inc. to Alter Domus (US) LLC.
• Unknown (executed) / recorded 2022-10-02 — Reel Not specified in Google Patents legal events
  • Conveyance: Release
  • Assignor: CORTLAND CAPITAL MARKET SERVICES LLC
  • Assignee: JUUL LABS, INC.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Release of security interest from Cortland Capital Market Services LLC back to Juul Labs Inc.
• Unknown (executed) / recorded 2022-12-10 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: JUUL LABS, INC.
  • Assignee: JLI NATIONAL SETTLEMENT TRUST
  • Correspondent: Not available from provided Google Patents data.
  • Context: Security interest granted by Juul Labs Inc. to JLI National Settlement Trust.
• Unknown (executed) / recorded 2022-12-23 — Reel 062114/0196
  • Conveyance: Corrective Assignment
  • Assignor: JUUL LABS, INC.
  • Assignee: JLI NATIONAL SETTLEMENT TRUST
  • Correspondent: Not available from provided Google Patents data.
  • Context: Corrective assignment to JLI National Settlement Trust to update the assignee address.
• Unknown (executed) / recorded 2023-07-11 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: ENVENIO INC., JUUL LABS, INC., VMR PRODUCTS LLC
  • Assignee: ALTER DOMUS (US) LLC
  • Correspondent: Not available from provided Google Patents data.
  • Context: Security interest granted by Juul Labs Inc. and related entities to Alter Domus (US) LLC.
• Unknown (executed) / recorded 2024-10-17 — Reel Not specified in Google Patents legal events
  • Conveyance: Release
  • Assignor: ALTER DOMUS (US) LLC
  • Assignee: JUUL LABS, INC., ENVENIO INC., VMR PRODUCTS LLC
  • Correspondent: Not available from provided Google Patents data.
  • Context: Release of security interest from Alter Domus (US) LLC back to Juul Labs Inc. and related entities.
• Unknown (executed) / recorded 2024-10-29 — Reel Not specified in Google Patents legal events
  • Conveyance: Assignment of Assignors Interest
  • Assignor: BOWEN, ADAM; XING, CHENYUE
  • Assignee: PLOOM, INC.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Recording of initial assignment from inventors to Ploom, Inc.
• Unknown (executed) / recorded 2024-10-29 — Reel Not specified in Google Patents legal events
  • Conveyance: Change of Name
  • Assignor: PLOOM, INC.
  • Assignee: PAX LABS, INC.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Recording of corporate name change from Ploom, Inc. to PAX Labs, Inc.
• Unknown (executed) / recorded 2024-10-29 — Reel Not specified in Google Patents legal events
  • Conveyance: Change of Name
  • Assignor: PAX LABS, INC.
  • Assignee: JUUL LABS, INC.
  • Correspondent: Not available from provided Google Patents data.
  • Context: Recording of corporate name change from PAX Labs, Inc. to Juul Labs, Inc.
• Unknown (executed) / recorded 2025-07-25 — Reel Not specified in Google Patents legal events
  • Conveyance: Security Interest
  • Assignor: JUUL LABS, INC.
  • Assignee: JLI NATIONAL SETTLEMENT TRUST
  • Correspondent: Not available from provided Google Patents data.
  • Context: Security interest granted by Juul Labs Inc. to JLI National Settlement Trust.

Timeline diagram

timeline
    title Ownership of US 12156533
    2013 : Priority Date
    2021 : Application filed by Juul
    2021 : Juul grants sec interest
    2021 : Juul grants sec interest
    2022 : Security interest released
    2022 : Juul grants sec interest
    2022 : Security interest released
    2022 : Juul to JLI Trust security
    2022 : Juul to JLI Trust corrective
    2023 : Juul et al grants sec int
    2024 : Sec int released to Juul et al
    2024 : Inventors assign to Ploom
    2024 : Ploom name changed to Pax
    2024 : Pax name changed to Juul
    2024 : Patent Granted
    2025 : Juul to JLI Trust security

NPE / troll-pattern signals

1. Shell-entity transfer — Present. The transfer of rights to JLI National Settlement Trust (recorded 2022-12-10, 2022-12-23, 2025-07-25) indicates a move from an operating company (Juul Labs Inc.) to an entity whose name ("Settlement Trust") suggests a focus on managing assets, often intellectual property, derived from litigation settlements, rather than manufacturing or product sales.
2. Known asserter in the chain — Present. JLI National Settlement Trust is listed as the current assignee involved in multiple litigation cases related to this patent, including a PTAB IPR (IPR2026-00161) where Unified Patents is the petitioner, suggesting that JLI National Settlement Trust is perceived as an asserting entity. Juul Labs Inc., as the plaintiff in the ITC and Arizona District Court cases, is asserting the patent, which is now held by JLI National Settlement Trust.
3. Repeat correspondent across the chain — Unclear. Correspondent information is not available from the provided Google Patents legal events data for any of the recorded assignments.
4. Cascading transfers — Unclear. While there are multiple security interests and releases, and the historical inventor-to-Juul chain was recorded with three distinct events on the same day (2024-10-29), these are mostly security transactions or historical corporate reorganizations, not necessarily consecutive ownership transfers to different shell entities for assertion purposes.
5. Pre-litigation transfer — Present. The last recorded security interest transfer to JLI National Settlement Trust occurred on 2025-07-25, which is less than a month before Juul Labs Inc. launched patent-infringement actions in August 2025 (e.g., ITC case 337-TA-1460 and Arizona District Court case 2:25-cv-02853). This timing suggests the transfer was arranged shortly before litigation to enable assertion.
6. Bankruptcy fire-sale — Not present. There is no evidence that Juul Labs Inc. or any prior assignee underwent bankruptcy proceedings leading to the sale of this patent. The transfers involving financial institutions are security interests, not distress sales.
7. Privateering — Present. Juul Labs Inc., an operating company, is the plaintiff in the active infringement suits (ITC and Arizona District Court cases) against competitors (Altria and NJOY). The patent's rights are held by JLI National Settlement Trust, suggesting an arrangement where the operating company asserts its IP through a separate entity, potentially to shield itself or manage litigation assets.
8. Defensive aggregator (anti-NPE) — Not present. The patent is currently being actively asserted in litigation by Juul Labs Inc. (via the trust), which is contrary to the purpose of a defensive aggregator.

Verdict

NPE — high confidence

The patent exhibits strong indicators of an NPE pattern. JLI National Settlement Trust, the current assignee/entity with security interest, functions as a shell entity for IP assertion. This entity is involved in active litigation as a defendant in a PTAB IPR, and the patent is being asserted by Juul Labs Inc. (an operating company) against competitors, which aligns with a privateering strategy. The security interest transfer to JLI National Settlement Trust on 2025-07-25 occurred just before the infringement lawsuits were filed in August 2025, a classic pre-litigation transfer signal.

USPTO Assignment Center search for US12156533: https://assignmentcenter.uspto.gov/patft/index.html

To identify the most relevant prior art for US patent 12156533, I will examine the "References Cited" section of the patent itself, as this typically includes the prior art considered by the patent examiner.

Here are some of the most relevant prior art documents cited in US Patent 12156533, along with their details and potential anticipation. Please note that a full anticipation analysis under 35 U.S.C. § 102 would require a detailed claim-by-claim comparison, which is beyond the scope of this response. The descriptions below highlight the general subject matter of the prior art and its relevance to the claims of US12156533.

Selected Prior Art References Cited in US12156533B2

1. U.S. Patent No. 9,215,895 (Hon)

   • Full Citation: US 9,215,895 B2
   • Publication/Filing Date: This patent is a "Related U.S. Application Data" listed, and the priority date of US12156533B2 is May 6, 2013. US 9,215,895 was issued on December 15, 2015, from an application filed on November 16, 2007 (US20090095318A1).
   • Brief Description: This patent generally relates to an electronic cigarette or "smokeless electronic atomizing cigarette" that delivers an atomized liquid, often containing nicotine, to a user. It describes various components of such devices, including atomizers, liquid reservoirs, and power sources.
   • Potential Anticipation (35 U.S.C. § 102): US 9,215,895 could potentially anticipate aspects of the device claims (e.g., claims relating to an "electronic cigarette" or "cartomizer" comprising a fluid storage compartment, atomizer, heating element, and mouthpiece) in US12156533B2. While US 9,215,895 likely describes a freebase nicotine solution, its teaching of the general electronic cigarette structure and function is highly relevant. Claims related to the specific nicotine salt formulations would likely not be directly anticipated by Hon, but the underlying device aspects could be.

2. U.S. Patent Application Publication No. 2013/0206148 (Alabaster)

   • Full Citation: US 2013/0206148 A1
   • Publication/Filing Date: Published August 8, 2013. This application has a priority date of February 6, 2012. Given that this publication date is after the May 6, 2013 priority date of US12156533, it would only be considered prior art if it claims priority to an earlier application that predates May 6, 2013. The PTAB challenge IPR2026-00161, however, did list it as prior art for US12156533, suggesting it has an effective priority date predating May 6, 2013.
   • Brief Description: While the full details are not provided in the snippet, generally, Alabaster patents in this field often relate to aerosol-generating devices and methods, including compositions for generating aerosols. Some Alabaster publications discuss nicotine salt formulations.
   • Potential Anticipation (35 U.S.C. § 102): Depending on its specific disclosures, US 2013/0206148 could potentially anticipate formulations comprising nicotine salts in biologically acceptable carriers, or methods of delivering nicotine via an electronic cigarette using such formulations. The extent of anticipation would depend on whether Alabaster explicitly discloses or renders obvious the specific characteristics of the acid used to form the nicotine salt (e.g., vapor pressure, melting/boiling points) or the specific pharmacokinetic profiles claimed in US12156533B2.

3. U.S. Patent Application Publication No. 2014/0000638 (Alabaster)

   • Full Citation: US 2014/0000638 A1
   • Publication/Filing Date: Published January 2, 2014. Similar to the above Alabaster publication, its publication date is after the May 6, 2013 priority date of US12156533. It would be considered prior art only if it has an effective priority date predating May 6, 2013. The PTAB IPR2026-00161 also listed this as prior art.
   • Brief Description: This patent application, like the other Alabaster references, generally concerns aerosol-generating devices and formulations. It could delve into different nicotine formulations or device designs.
   • Potential Anticipation (35 U.S.C. § 102): Similar to the previous Alabaster reference, this could potentially anticipate various aspects of the nicotine salt liquid formulations, methods of delivery, or components of electronic cigarettes, depending on its specific disclosures and effective filing date relative to US12156533B2's priority date.

4. U.S. Patent No. 8,881,732 (Monsees)

   • Full Citation: US 8,881,732 B2
   • Publication/Filing Date: Issued November 11, 2014, from an application filed on April 11, 2012. This would generally be considered prior art to US12156533B2 given its earlier filing date.
   • Brief Description: Monsees patents frequently cover electronic cigarettes, their components, and methods of use. This patent likely describes an electronic cigarette device for vaporizing a liquid to create an inhalable aerosol, potentially including various liquid compositions.
   • Potential Anticipation (35 U.S.C. § 102): US 8,881,732 could potentially anticipate the broader aspects of the electronic cigarette device claims, methods of operating an electronic cigarette, and formulations involving liquid carriers. If it discloses nicotine salt formulations with specific acid characteristics or pharmacokinetic profiles claimed in US12156533B2, it could also anticipate those aspects.

5. U.S. Patent No. 8,322,350 (Lipowicz)

   • Full Citation: US 8,322,350 B2
   • Publication/Filing Date: Issued December 4, 2012. The application priority date is October 15, 2008.
   • Brief Description: This patent describes an aerosol generator device for delivering an aerosol of a nicotine salt. The device includes a first chamber with liquid nicotine, a second chamber with a volatile acid solution, and a third chamber where nicotine vapor and acid vapor are mixed to form a nicotine salt aerosol.
   • Potential Anticipation (35 U.S.C. § 102): US 8,322,350 is highly relevant as it explicitly teaches an "aerosol generator device for delivering an aerosol of a nicotine salt." This directly addresses the concept of generating nicotine salt aerosols, which is central to US12156533B2. Claims in US12156533B2 related to a "method of delivering nicotine to a user comprising operating an electronic cigarette...wherein the electronic cigarette comprises a nicotine salt formulation" or a "nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol" could be anticipated. The key distinction, if any, for US12156533B2's claims would likely lie in the specific characteristics of the acid used to form the salt (e.g., vapor pressure, melting/boiling points) or the unique pharmacokinetic profile achieved, if these are not explicitly or inherently disclosed by Lipowicz.

6. U.S. Patent No. 10,952,468

   • Full Citation: US 10,952,468 B2
   • Publication/Filing Date: Issued March 23, 2021. This patent is a continuation of US Patent 10,952,468, which is itself a continuation of an application filed on May 6, 2014, claiming priority to provisional applications filed December 5, 2013, and May 6, 2013. This patent is explicitly identified as a parent application of US12156533B2 ("This application is a continuation of U.S. application Ser. No. 14/925,961 filed Oct. 28, 2015, issued as U.S. Pat. No. 10,952,468, which is a continuation of U.S. application Ser. No. 14/271,071 filed May 6, 2014, which claims the benefit of priority to U.S. Application No. 61/912,507 filed Dec. 5, 2013, and U.S. Application No. 61/820,128 filed May 6, 2013"). Therefore, while it is cited, it is part of the same patent family and shares the same priority date of May 6, 2013, meaning it cannot anticipate US12156533B2 under 35 U.S.C. § 102. It is an important reference for understanding the full scope of the invention and its prosecution history.

This analysis focuses on the general subject matter of the prior art and its potential relevance. A complete legal analysis would necessitate a thorough review of the full text of each cited patent and a direct comparison to each claim of US12156533B2.

US patent 12156533 (US'533) relates to nicotine salt formulations for aerosol devices, specifically electronic cigarettes, and methods for their use, aiming to provide improved nicotine delivery and user satisfaction. An analysis of obviousness under 35 U.S.C. § 103 requires identifying prior art that would have motivated a person having ordinary skill in the art (PHOSITA) to combine known elements to arrive at the claimed invention with a reasonable expectation of success.

Since the provided patent text does not explicitly list external prior art documents, this analysis will rely on the general state of the art and common knowledge in the field of electronic cigarettes and nicotine formulations as implied and discussed within the patent itself prior to its priority date of May 6, 2013.

Implied Prior Art References

1. Prior Art Reference 1 (PA1): Electronic Cigarettes with Freebase Nicotine: Electronic cigarettes comprising a heating element, a liquid reservoir, and a biologically acceptable liquid carrier (such as propylene glycol and/or vegetable glycerin) for delivering freebase nicotine in an inhalable aerosol were well-known prior to the priority date of US'533. The patent itself discusses and compares its nicotine salt formulations to "nicotine freebase formulations" and notes the "lack of satisfaction of free base nicotine".
2. Prior Art Reference 2 (PA2): General Knowledge of Nicotine Salts: It was known in the art that nicotine, as an alkaloid, could form salts with various organic and inorganic acids. The patent's "Prior art keywords" include "nicotine salt" and "acid", and the patent refers to "Conflicting reports have been published regarding the transfer efficiency of free base nicotine in comparison to mono- or di-protonated nicotine salts". This indicates that nicotine salts were an explored alternative to freebase nicotine in delivery systems.
3. Prior Art Reference 3 (PA3): Basic Principles of Aerosolization Chemistry: Fundamental chemical engineering principles dictate that the physical properties of components in a liquid formulation, such as vapor pressure, melting point, and boiling point, are critical for efficient aerosol generation when heated. A PHOSITA would understand that materials need to be volatile enough to vaporize effectively at the device's operating temperature without decomposing.

Obviousness Argument Under 35 U.S.C. § 103

A PHOSITA in the field of e-cigarette liquid formulation, prior to May 6, 2013, would have been motivated to combine PA1, PA2, and PA3 to improve the user experience and nicotine delivery efficiency of electronic cigarettes.

Motivation for Combination:
Existing e-cigarettes using freebase nicotine (PA1) presented challenges related to user satisfaction and potentially the efficiency of nicotine transfer. The patent explicitly states that freebase nicotine compositions' delivery of nicotine to blood is "not necessarily comparable in blood plasma levels (Cmax and Tmax) to a traditional cigarette's nicotine delivery to blood when inhaled" and can lead to a "lack of satisfaction". This would provide a strong motivation for a PHOSITA to seek alternatives.

Given the general knowledge of nicotine salts (PA2) as a way to modify nicotine's properties, a PHOSITA would naturally consider incorporating them into e-cigarette formulations to address these deficiencies. To ensure that these nicotine salt formulations effectively generate an inhalable aerosol in a heated e-cigarette device (PA1), the PHOSITA would apply basic principles of aerosolization chemistry (PA3).

Specifically, the PHOSITA would be motivated to select acids for salt formation whose physical properties (vapor pressure, melting point, boiling point) are suitable for the typical operating temperatures of an e-cigarette (e.g., 150°C to 250°C, or 180°C to 220°C, as mentioned in the patent). The patent itself suggests this line of reasoning by stating, "the optimal nicotine salt formulation may be determined by the vapor pressure of the constituent acid," and "the nicotine salt formulations comprise an acid with a vapor pressure that is similar to the vapor pressure of free base nicotine". The goal would be to achieve efficient co-vaporization of the nicotine (either as the salt or after dissociation to freebase) and the acid, leading to improved delivery.

Through routine experimentation and optimization, a PHOSITA, guided by these motivations and principles, would systematically test various known organic acids (e.g., salicylic acid, benzoic acid, lauric acid, levulinic acid, sorbic acid, pyruvic acid, which are all mentioned in the patent) whose physical properties are readily available in chemical databases. This routine optimization process could lead to the selection of acids falling within the claimed ranges for:

• Vapor pressure (>20 mmHg at 200°C, or about 20 to 200 mmHg at 200°C).
• Melting point (<160°C, boiling point >160°C, and at least a 50-degree difference between melting point and boiling point).
• Melting point at least 40 degrees lower than an operating temperature, boiling point no more than 40 degrees lower than the operating temperature, and at least a 50-degree difference between the melting point and the boiling point.

The selection of these specific ranges of physical properties, while presented as inventive in US'533, could be seen as an expected outcome of a PHOSITA's routine efforts to optimize aerosolization parameters given the operating conditions of e-cigarettes.

Addressing Claims of Unexpected Results:
The patent counters obviousness by highlighting "unpredictable results" and "unexpected" performance, particularly regarding the rapid rate of nicotine uptake in the blood (e.g., at least 5 ng/mL at about 1.5 minutes after a first puff) and superior user satisfaction compared to freebase nicotine and other nicotine salts. The patent states, "nicotine salt formulations delivered using an e-cigarette appear comparable in Cmax and Tmax values (measuring blood plasma nicotine levels), however, not all nicotine salts perform similarly to each other or to a traditional cigarette with respect to the rate of nicotine uptake in the blood at early time periods (0-1.5 minutes). These results are unexpected".

While such unexpected results can be compelling evidence of non-obviousness, an obviousness argument would still contend that the initial motivation to combine known elements and approach the problem of improving nicotine delivery with specific acid property considerations was present. The discovery of particularly effective acids within a broader, obvious-to-explore range, or the quantification of a surprisingly good pharmacokinetic profile, might be considered a matter of degree or a "hope for success" that was ultimately realized, rather than an unmotivated departure from the prior art. For a claim to be considered obvious, it is not necessary that the exact results be predictable, only that a PHOSITA would have had reason to combine the prior art elements with a reasonable expectation of some improvement. The patent's own description of exploring various nicotine salts and their properties suggests an iterative optimization process, which can sometimes lead to results that, while better than anticipated, might still fall within the realm of routine experimentation.

US Patent 12156533B2, titled "Nicotine salt formulations for aerosol devices and methods thereof," was filed on February 9, 2021, and issued on December 3, 2024. The patent is currently active and is expected to expire on March 18, 2035.

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is granted to compensate applicants for delays caused by the USPTO during the prosecution of a utility or plant patent application. This adds time to the standard 20-year patent term from the earliest filing date. The USPTO automatically determines the PTA period and provides notice on or before the patent's issuance date.

To find the specific PTA granted for US12156533B2, one would typically look at the face of the issued patent or its electronic file wrapper in Patent Center. However, this detailed PTA information is not available in the provided Google Patents snippet or the search results.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is available for patents claiming certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products to restore patent term lost due to delays in obtaining regulatory approval from agencies like the FDA. A PTE application must be submitted within 60 days of regulatory approval, and the patent must not have expired or been previously extended. Only one PTE is granted per regulatory review period, even if multiple patents cover the approved product.

There is no indication in the provided patent information or search results that US12156533B2 has received a Patent Term Extension (PTE) under 35 U.S.C. § 156. Such extensions are typically for products requiring regulatory approval, and while the patent relates to nicotine formulations for electronic cigarettes, which are regulated, the specific grant of a PTE is not noted.

Continuation and Divisional Applications

The patent explicitly states that it is a continuation application: "This application is a continuation of U.S. application Ser. No. 14/925,961 filed Oct. 28, 2015, issued as U.S. Pat. No. 10,952,468, which is a continuation of U.S. application Ser. No. 14/271,071 filed May 6, 2014, which claims the benefit of priority to U.S. Application No. 61/912,507 filed Dec. 5, 2013, and U.S. Application No. 61/820,128 filed May 6, 2013, which are incorporated herein by reference in their entireties."

This indicates the following chain of applications:

• U.S. Provisional Application No. 61/820,128, filed May 6, 2013 (priority date)
• U.S. Provisional Application No. 61/912,507, filed Dec. 5, 2013
• U.S. Application Ser. No. 14/271,071, filed May 6, 2014 (non-provisional, claims benefit of 61/820,128 and 61/912,507)
• U.S. Application Ser. No. 14/925,961, filed Oct. 28, 2015, issued as U.S. Pat. No. 10,952,468 (continuation of 14/271,071)
• U.S. Application Ser. No. 17/171,976, filed Feb. 9, 2021 (the application for US12156533B2, which is a continuation of 14/925,961)

The patent also mentions it is related to U.S. application Ser. No. 14/512,311, issued as U.S. Pat. No. 9,215,895, and to U.S. application Ser. No. 14/925,968. These are other family members, potentially continuations, divisionals, or continuation-in-parts.

Related Family Members

Based on the patent's cross-reference section, the following are related family members:

• U.S. Pat. No. 10,952,468 (parent continuation application, Ser. No. 14/925,961)
• U.S. Application Ser. No. 14/271,071 (parent continuation application)
• U.S. Provisional Application No. 61/912,507 (priority application)
• U.S. Provisional Application No. 61/820,128 (priority application)
• U.S. Pat. No. 9,215,895 (related application, Ser. No. 14/512,311)
• U.S. Application Ser. No. 14/925,968 (related application)
• US20210186082A1 (other version/publication of the same family)

Additionally, the Google Patents information lists further priority claims, indicating additional family members and their priorities:

• Priority to US18/939,841 (2024-11-07)
• Priority to US19/021,904 (2025-01-15)
• Priority to US19/024,843 (2025-01-16)

These are likely further continuation or divisional applications within the same patent family, claiming priority back to the original May 6, 2013 date.

Projected Expiration Date

The patent is currently active and is expected to expire on March 18, 2035.

The standard patent term is 20 years from the earliest filing date of the application from which priority is claimed. In this case, the earliest priority date is May 6, 2013, from U.S. Provisional Application No. 61/820,128. A 20-year term from this date would be May 6, 2033.

The listed expiration date of March 18, 2035, indicates that there has been a Patent Term Adjustment (PTA) of approximately 1 year and 10 months (from May 6, 2033, to March 18, 2035). This adjustment would compensate for delays during the patent's prosecution at the USPTO. The patent document itself indicates an "Adjusted expiration" date of March 18, 2035.

Defensive Disclosure Document for US Patent 12156533

This document outlines derivative variations and extensions of the core claims of US Patent 12156533 ("Nicotine salt formulations for aerosol devices and methods thereof"). The purpose of this disclosure is to create readily accessible prior art that could render future incremental improvements by competitors obvious or non-novel, thereby strengthening the defensive position of the technology.

The analysis focuses on three representative independent claims:

1. A method of delivering nicotine (based on acid vapor pressure >20 mmHg at 200° C.).
2. A nicotine salt liquid formulation (based on acid vapor pressure >20 mmHg at 200° C.).
3. An electronic cigarette device (comprising a fluid storage compartment, heater, battery, mouthpiece, and formulation with acid vapor pressure >20 mmHg at 200° C.).

For each core claim, five derivative variations are generated across different axes: Material & Component Substitution, Operational Parameter Expansion, Cross-Domain Application, Integration with Emerging Tech, and The "Inverse" or Failure Mode.

---

Derivatives of Core Method Claim: A method of delivering nicotine to a user comprising operating an electronic cigarette to a user wherein the electronic cigarette comprises a nicotine salt formulation comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure >20 mmHg at 200° C., and inhaling an aerosol generated from the nicotine salt formulation heated by the electronic cigarette.

Derivative 1.1: Material & Component Substitution - Piezoelectric Atomization with Inorganic Acid Salt

• Enabling Description: A method of delivering nicotine comprising operating an electronic aerosolization device utilizing a piezoelectric atomizer (e.g., using a lead zirconate titanate (PZT) ceramic element) instead of a resistive heating element. The device contains a nicotine salt formulation where the nicotine salt is formed with an inorganic acid, specifically phosphoric acid (H₃PO₄), characterized by a vapor pressure >20 mmHg at 200°C (e.g., approximately 50 mmHg at 200°C, under reduced pressure or as part of a mixture). The biologically acceptable liquid carrier comprises a blend of polyethylene glycol (PEG 400) and ethanol (70:30 v/v). The piezoelectric element, operating at a frequency of 100-200 kHz (e.g., 108 kHz), creates ultrasonic vibrations that generate a fine aerosol mist (e.g., 1-5 µm particle size) from the formulation, which is then inhaled by the user. The phosphoric acid salt ensures protonation stability during aerosolization and potentially alters absorption kinetics due to its strong acidity compared to typical organic acids.
• Combination Prior Art: This derivative combines US12156533 with ISO 20770:2007 (E-liquid quality standards for non-vaporization aspects) and IEC 62133 (Battery safety standard for portable devices).
• Mermaid Diagram:

  flowchart TD
      A[Start Method] --> B{Load PEG/Ethanol + Nicotine Phosphate Formulation};
      B --> C[Activate Piezoelectric Atomizer (PZT Element)];
      C --> D{Ultrasonic Vibrations (100-200 kHz)};
      D --> E[Aerosol Mist Generation (1-5 µm)];
      E --> F[Inhale Aerosol];
      F --> G[End Method];
  

Derivative 1.2: Operational Parameter Expansion - Extreme Temperature and Pulsed-Flow Delivery

• Enabling Description: A method of delivering nicotine comprising operating an electronic aerosolization device under extreme thermal conditions and pulsed-flow delivery profiles.
  • Extreme High-Temperature (350-400°C) with Micro-Pulse Flow: The device operates with an internal heating element (e.g., refractory metal alloy coil) maintaining a temperature range of 350°C to 400°C. The nicotine salt formulation uses maleic acid (a dicarboxylic acid) to form the nicotine salt, with maleic acid characterized by a vapor pressure >500 mmHg at 400°C (e.g., via advanced thermal modeling or experimental data, considering its boiling point and decomposition profile). The method involves a micro-pulse flow of formulation (e.g., 10-50 µL per pulse) delivered at rapid, discrete intervals (e.g., 100-500 ms duration every 2 seconds), optimized for instantaneous flash vaporization. This rapid, high-temperature aerosolization aims for complete dissociation and transfer, suitable for high-efficiency delivery or industrial testing.
  • Cryogenic-Assisted Low-Temperature (50-80°C) with Extended Exposure: The device incorporates a localized thermoelectric cooler (TEC) to pre-cool the liquid carrier (e.g., a low-volatility ionic liquid blend) to 0-10°C before instantaneous heating by a low-power resistive element to 50°C to 80°C. The nicotine salt is formed with formic acid (VP >100 mmHg at 80°C, considering its low boiling point and high volatility), facilitating aerosolization at very low temperatures. The inhalation involves extended, shallow puffs (e.g., 5-10 seconds duration) with a prolonged post-aerosolization dwell time (e.g., 2-3 seconds) in an expansion chamber to allow for particle growth and stabilization before inhalation, targeting lung deposition for specific therapeutic applications at minimal thermal stress.
• Combination Prior Art: This derivative combines US12156533 with ASTM E2188 (Standard Guide for the Characterization of Aerosol Emissions) and a pharmaceutical manufacturing standard (e.g., ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients).
• Mermaid Diagram:

  graph TD
      A[Start Method] --> B{Select Operational Mode};
      B -- Extreme High-Temp --> C1[Set Heater: 350-400°C];
      C1 --> D1[Micro-Pulse Flow (10-50 µL/pulse, 2s interval)];
      D1 --> E1[Flash Vaporization (Nicotine Maleate)];
      B -- Cryogenic-Assisted Low-Temp --> C2[Pre-Cool Carrier (0-10°C)];
      C2 --> D2[Heat to 50-80°C (Nicotine Formate)];
      D2 --> E2[Extended Puff (5-10s) & Dwell Time (2-3s)];
      E1 & E2 --> F[Inhale Aerosol];
      F --> G[End Method];
  

Derivative 1.3: Cross-Domain Application - Bio-Aerosol Delivery for Indoor Farming

• Enabling Description: A method for delivering aerosolized bio-stimulants or pest control agents in indoor vertical farms. An electronic aerosolization system, structurally and functionally analogous to an e-cigarette, dispenses a formulation containing a biologically active compound (e.g., Bacillus subtilis spores or a plant-derived peptide biostimulant) complexed with a biodegradable organic acid (e.g., succinic acid, characterized by a vapor pressure >20 mmHg at 200°C). The active compound-acid complex is suspended in a biologically acceptable, nutrient-rich carrier (e.g., a hydro-alcoholic solution of humic acids and micronutrients). The system is integrated into an environmental control unit (ECU) of a vertical farm, operating autonomously based on sensor data (e.g., plant stress detection, pest density). The aerosolization device heats the formulation to a precise temperature (e.g., 180°C), generating a fine mist for uniform foliar application, enhancing plant growth or combating pathogens without direct liquid runoff. The "mouthpiece" is replaced by an array of precision nozzles.
• Combination Prior Art: This derivative combines US12156533 with ISO 17357-1 (Crop protection equipment - sprayer types) and ANSI/ASHRAE Standard 126 (Method of Testing Thermal and Flow Performance for Agricultural Systems).
• Mermaid Diagram:

  graph TD
      A[Farm ECU/Sensors] --> B{Trigger Bio-Aerosol Application};
      B --> C[Load Bio-Stimulant/Pesticide (Succinic Acid Complex)];
      C --> D[Electronic Aerosolization System];
      D --> E[Heater (180C) & Atomizer];
      E --> F[Precision Nozzle Array];
      F --> G[Uniform Foliar Application];
      G --> H[Monitor Plant Response];
      H --> I[End Application Cycle];
  

Derivative 1.4: Integration with Emerging Tech - AI-Optimized Biofeedback Delivery

• Enabling Description: A method of delivering nicotine comprising operating an electronic cigarette integrated with a closed-loop AI-driven biofeedback system. The device features real-time physiological sensors (e.g., non-invasive transdermal galvanic skin response (GSR) sensors on the device body, pupil dilation tracking via a micro-camera in the mouthpiece, and integrated EEG electrodes in an accompanying wearable band). An onboard AI/ML inference engine (e.g., a TinyML model running on an edge processor) continuously processes this biofeedback, along with puff dynamics (duration, intensity, flow rate). The AI dynamically adjusts the heating element temperature (e.g., within a 170-230°C range), coil resistance, and airflow to optimize the nicotine delivery profile (e.g., Cmax and Tmax for specific satisfaction levels or craving reduction) for the individual user in real-time. The nicotine salt formulation utilizes nicotine lactate, with lactic acid characterized by a vapor pressure >20 mmHg at 200°C, and the AI optimizes the transient acid-nicotine dissociation for maximum bio-availability per puff based on the user's current physiological state. This system also integrates with a secure federated learning platform to improve overall personalization models without compromising individual user data.
• Combination Prior Art: This derivative combines US12156533 with IEEE 802.15.4 (IoT communication standard for local sensor data), HL7 FHIR (healthcare data exchange standard for physiological data integration), and OpenFL (open-source federated learning framework).
• Mermaid Diagram:

  sequenceDiagram
      participant U as User
      participant ECS as E-Cigarette System
      participant Sensors as On-Device/Wearable Sensors
      participant AI as AI/ML Inference Engine
      participant Cloud as Federated Learning Cloud
  
      U->>ECS: Initiates Puff
      ECS->>Sensors: Activates Sensors (GSR, Pupil, EEG)
      Sensors->>AI: Transmits Real-time Biofeedback
      ECS->>AI: Transmits Puff Dynamics (Flow, Duration)
      AI->>AI: Processes Biofeedback & Puff Data
      AI->>AI: Adjusts Heating, Coil Resistance, Airflow
      AI->>ECS: Sends Optimized Device Parameters
      ECS->>U: Delivers Personalized Nicotine Aerosol (Nicotine Lactate)
      AI->>Cloud: (Periodically) Sends Aggregated, Anonymized Model Updates
      Cloud->>AI: (Periodically) Receives Global Model Updates
  

Derivative 1.5: The "Inverse" or Failure Mode - Self-Deactivating Biodegradable Therapeutic System

• Enabling Description: A method of delivering nicotine using an electronic cigarette designed with an inherent self-deactivation mechanism at its end-of-life or upon misuse, targeting safe disposal and environmental impact mitigation, particularly for therapeutic nicotine delivery systems. The electronic cigarette's fluid storage compartment contains a nicotine salt formulation (e.g., nicotine succinate, where succinic acid has a vapor pressure >20 mmHg at 200°C) within a biodegradable polymer matrix (e.g., polylactic acid, PLA) that slowly dissolves over a fixed therapeutic period (e.g., 30 days). Once the matrix fully degrades, a micro-capsule containing a pH-altering catalyst (e.g., an immobilized enzyme like nicotine oxidase or a strong base like sodium bicarbonate) is released into the remaining formulation. This catalyst rapidly neutralizes or degrades the residual nicotine and its salt, rendering the formulation non-functional and non-aerosolizable within a few hours. Concurrently, the device's internal power management unit, sensing the degradation of the formulation, irreversibly disables the heating element and signals end-of-life via an indicator. The device casing itself is made from a bio-derived, compostable polymer, simplifying environmental disposal.
• Combination Prior Art: This derivative combines US12156533 with ASTM D6400 (Standard Specification for Labeling Products Composting in Municipal and Industrial Facilities) and ISO 14021 (Environmental labels and declarations - Self-declared environmental claims).
• Mermaid Diagram:

  stateDiagram-v2
      state "Active Therapeutic Use" as Active
      state "End-of-Life Triggered" as EOL_Trigger
      state "Formulation Self-Deactivation" as Self_Deact
      state "Device Permanent Disable" as Device_Disable
      state "Safe Disposal" as Safe_Disposal
  
      [*] --> Active: Start Therapeutic Period
      Active --> Active: Daily Nicotine Delivery (Nicotine Succinate)
      Active --> EOL_Trigger: Polymer Matrix Degrades (e.g., after 30 days)
      EOL_Trigger --> Self_Deact: pH-Altering Catalyst Released
      Self_Deact --> Self_Deact: Nicotine Degradation/Neutralization
      EOL_Trigger --> Device_Disable: Power Unit Disables Heater
      Self_Deact --> Device_Disable: (Signals Completion)
      Device_Disable --> Safe_Disposal: User Disposes of Compostable Device
      Safe_Disposal --> [*]
  

---

Derivatives of Core Formulation Claim: A nicotine salt liquid formulation in an electronic cigarette for generating an inhalable aerosol upon heating in the electronic cigarette, the formulation in the cigarette comprising a nicotine salt in a biologically acceptable liquid carrier wherein an acid used to form said nicotine salt is characterized by vapor pressure >20 mmHg at 200° C.

Derivative 2.1: Material & Component Substitution - High-Purity (S)-Nicotine with Glycolic Acid and Silicone-Ionic Liquid Carrier

• Enabling Description: A nicotine salt liquid formulation comprising synthetic, enantiomerically pure (S)-nicotine (≥99.5% chiral purity) as the active pharmaceutical ingredient (API). The nicotine salt is formed with glycolic acid (2-hydroxyacetic acid), an alpha-hydroxy acid, characterized by a vapor pressure of approximately 100 mmHg at 200°C (extrapolated from its boiling point of 158°C at 760 mmHg, indicating significant volatility at 200°C). The biologically acceptable liquid carrier is a novel blend of a low-molecular-weight silicone oil (e.g., polydimethylsiloxane, viscosity 5 cSt, medical grade) and a pharmaceutical-grade ionic liquid (e.g., 1-butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, [BMIM][TFSI]). This carrier system is designed to provide enhanced thermal stability, reduce carbonyl formation upon heating, and offer superior wetting properties for atomizer wicks compared to traditional glycol-based carriers. The specific interaction of (S)-nicotine glycolate with the silicone-ionic liquid blend is optimized for controlled dissociation during aerosolization.
• Combination Prior Art: This derivative combines US12156533 with USP <611> (Elixirs, Tinctures, and Syrups - pharmaceutical preparation standards) and REACH regulations for silicone-based emollients and ionic liquids.
• Mermaid Diagram:

  classDiagram
      class NicotineGlycolateFormulation {
          + (S)-Nicotine (synthetic, >=99.5% pure)
          + GlycolicAcid "alpha-hydroxy acid, VP ~100mmHg@200C"
          + SiliconeOil "PDMS, 5 cSt, medical grade"
          + IonicLiquid "[BMIM][TFSI], pharm grade"
          + LiquidCarrier "Silicone Oil + Ionic Liquid"
          + NicotineGlycolateSalt
      }
      class ElectronicCigarette {
          + HeatingElement
          + FluidStorageCompartment
          + Battery
          + Mouthpiece
      }
      NicotineGlycolateFormulation "1" *-- "1" NicotineGlycolateSalt : comprises
      NicotineGlycolateFormulation "1" *-- "1" LiquidCarrier : uses_as
      NicotineGlycolateSalt "1" *-- "1" GlycolicAcid : formed_with
      NicotineGlycolateSalt "1" *-- "1" (S)-Nicotine : formed_from
      ElectronicCigarette "1" *-- "1" NicotineGlycolateFormulation : contains
  

Derivative 2.2: Operational Parameter Expansion - High-Altitude/Low-Pressure Stable Formulation

• Enabling Description: A nicotine salt liquid formulation engineered for stable and efficient aerosol generation in low-pressure, high-altitude environments (e.g., aircraft cabins, mountaineering, or simulated aerospace conditions). The formulation utilizes nicotine trifluoroacetate as the nicotine salt, formed from trifluoroacetic acid (TFA). TFA is characterized by an exceptionally high vapor pressure (>1000 mmHg at 200°C, due to its boiling point of 72°C) and strong acidity, ensuring efficient nicotine dissociation and volatilization even at significantly reduced ambient pressures. The biologically acceptable liquid carrier comprises a blend of a high-thermal-stability perfluorocarbon liquid (e.g., perfluorodecalin) and a pharmaceutical-grade, low-freezing point co-solvent (e.g., dimethyl sulfoxide (DMSO)). This carrier system maintains fluidity and homogeneity across a wide temperature range (e.g., -60°C to +80°C for storage, and 150-250°C for operation) and prevents premature boiling or excessive evaporation of carrier components under low atmospheric pressure, ensuring consistent dose delivery regardless of external pressure variations.
• Combination Prior Art: This derivative combines US12156533 with ISO 14644 (Cleanrooms and associated controlled environments for manufacturing) and NASA-STD-6001 (Flammability, Odor, Offgassing, and Compatibility Requirements and Test Procedures for Materials in Environments that Support Combustion).
• Mermaid Diagram:

  flowchart LR
      subgraph High-Altitude/Low-Pressure Formulation
          N[Nicotine Trifluoroacetate Salt] --> C1(Perfluorocarbon Liquid);
          N --> C2(Dimethyl Sulfoxide (DMSO));
          C1 & C2 --> F(Robust Formulation Blend);
      end
      subgraph Electronic Cigarette Device
          F --> H[Heater Element];
          H --> A[Atomization Chamber];
          A --> O[Output Aerosol];
      end
      F -- "Designed for" --> E[Low-Pressure Environments (e.g., <760 mmHg)];
      N -- "Formed from" --> TFA(Trifluoroacetic Acid (VP >1000mmHg@200C));
  

Derivative 2.3: Cross-Domain Application - Antimicrobial Aerosol for HVAC Systems

• Enabling Description: A liquid formulation for generating an aerosolized broad-spectrum antimicrobial agent for airborne disinfection within large-scale Heating, Ventilation, and Air Conditioning (HVAC) systems in public buildings or healthcare facilities. The formulation comprises an antimicrobial active (e.g., quaternary ammonium compound, QAC) complexed with a food-grade organic acid (e.g., sorbic acid, characterized by a vapor pressure >20 mmHg at 200°C). The QAC-sorbate complex is dissolved in a carrier consisting of food-grade glycerol and deionized water (80:20 v/v). This formulation is designed to be highly stable in storage and efficiently aerosolizable without thermal degradation of the antimicrobial component. When heated (e.g., to 180°C) by an industrial aerosolization unit integrated into the HVAC ductwork, it generates a fine, inhalable mist (e.g., 0.5-10 µm) that effectively disperses throughout the air volume, inactivating airborne bacteria and viruses. The "nicotine salt" principle is repurposed for antimicrobial delivery, leveraging the controlled volatilization of the acid for efficient dispersion.
• Combination Prior Art: This derivative combines US12156533 with FDA Food Code (for food-grade components), ASHRAE Standard 62.1 (Ventilation for Acceptable Indoor Air Quality), and ISO 22000 (Food safety management systems for production).
• Mermaid Diagram:

  classDiagram
      class AntimicrobialFormulation {
          + QuaternaryAmmoniumCompound (QAC)
          + SorbicAcid "Food-grade, VP >20mmHg@200C"
          + Glycerol_Water_Blend "Food-grade carrier (80:20 v/v)"
          + QAC_Sorbate_Complex "Antimicrobial salt-like complex"
      }
      class HVAC_Aerosolizer {
          + IndustrialHeatingElement
          + FluidReservoir
          + AtomizationNozzleArray
          + HVACDuctIntegration
      }
      AntimicrobialFormulation "1" *-- "1" QAC_Sorbate_Complex : comprises
      AntimicrobialFormulation "1" *-- "1" Glycerol_Water_Blend : uses_as
      QAC_Sorbate_Complex "1" *-- "1" SorbicAcid : formed_with
      HVAC_Aerosolizer "1" *-- "1" AntimicrobialFormulation : contains
      HVAC_Aerosolizer --|> AirDisinfectionSystem : integrates_with
  

Derivative 2.4: Integration with Emerging Tech - AI-Adaptive & Blockchain-Verified "Smart" Formulation

• Enabling Description: A nicotine salt liquid formulation designed as an AI-adaptive and blockchain-verified "smart" formulation. The formulation contains microencapsulated pH-sensitive or thermochromic dyes and non-toxic quantum dots (QDs) that serve as intrinsic chemical and thermal degradation indicators. An electronic cigarette cartridge, equipped with an integrated micro-spectrometer and a specialized optical sensor, continuously monitors these indicators. An on-board AI module analyzes the spectral data from the QDs and dyes to detect changes in pH, temperature excursions, and early-stage degradation product formation, predicting the formulation's remaining shelf life and optimal operating parameters. This AI can trigger the release of a precisely dosed, encapsulated antioxidant (e.g., alpha-tocopherol) from an adjacent micro-reservoir within the cartridge to extend shelf life or stabilize the nicotine salt (e.g., nicotine benzoate, with benzoic acid VP >20 mmHg at 200°C). Furthermore, each formulation batch is registered on a publicly verifiable blockchain ledger (e.g., using a W3C Verifiable Credentials Data Model). The cartridge has an embedded NFC chip that allows the electronic cigarette device to query the blockchain, verifying the batch's full provenance, quality control history, and recommended AI operational profiles from manufacturer to point of use, guaranteeing authenticity and optimal performance.
• Combination Prior Art: This derivative combines US12156533 with IEEE 2413 (Standard for an Architectural Framework for the Internet of Things), ISO 10993 (Biological evaluation of medical devices for biocompatibility of additives), and W3C Verifiable Credentials Data Model (for digital proof of provenance).
• Mermaid Diagram:

  sequenceDiagram
      participant Formula as Smart Nicotine Salt Formulation
      participant Cartridge as Cartridge w/ Sensors/AI
      participant EC as E-Cigarette Device
      participant Blockchain as Public Blockchain Ledger
      participant AI as On-Board AI Module
  
      Formula->>Cartridge: Contains QDs, Dyes, Micro-antioxidant
      Cartridge->>EC: Loaded into device
      EC->>Cartridge: Activates Micro-Spectrometer & Optical Sensors
      Cartridge->>AI: Streams Spectral Data (QDs, Dyes)
      AI->>AI: Analyzes Data, Predicts Degradation/Shelf-Life
      AI->>Cartridge: If Degradation Predicted: Triggers Antioxidant Release
      Cartridge->>Formula: Releases Antioxidant
      EC->>Blockchain: Queries NFC for Batch ID & Verifiable Credentials
      Blockchain-->>EC: Returns Provenance & QC History
      EC->>AI: Provides Provenance Data to AI
      AI->>EC: Adjusts Device Parameters for Optimal Formulation Use
  

Derivative 2.5: The "Inverse" or Failure Mode - Self-Quenching, Flavor-Masking Formulation

• Enabling Description: A nicotine salt liquid formulation designed with a two-stage self-quenching mechanism upon tamper detection or accidental prolonged exposure to air. The formulation comprises a nicotine salt (e.g., nicotine pyruvate, where pyruvic acid has a vapor pressure >20 mmHg at 200°C) and a primary carrier system (e.g., propylene glycol/vegetable glycerin).
  • Stage 1 (Tamper/Exposure Detection): The cartridge is engineered with a frangible seal or an oxygen-sensitive membrane. If breached (tampering) or exposed to ambient air for an extended period (e.g., >24 hours), it triggers the release of an encapsulated, non-toxic flavor-masking bitterant (e.g., denatonium benzoate) and a colorimetric indicator (e.g., food-grade blue dye) into the main formulation. This immediately signals compromise and makes the product unappealing.
  • Stage 2 (Nicotine Degradation): Simultaneously, or slightly delayed, a second micro-capsule releases a chemical scavenger (e.g., a strong non-volatile proton acceptor like polyethyleneimine, PEI) that irreversibly binds to the freebase nicotine (formed from the dissociation of nicotine pyruvate upon heating) and rapidly quenches any remaining pyruvic acid, forming a high-molecular-weight, non-volatilizable complex. This drastically reduces the effective nicotine concentration and aerosolization efficiency. The pyruvic acid's inherent reactivity also contributes to rapid quenching with PEI. This design ensures that a compromised formulation quickly becomes unpalatable, visually marked as "bad," and functionally non-delivering of nicotine.
• Combination Prior Art: This derivative combines US12156533 with ASTM D5511 (Standard Test Method for Determining Anaerobic Biodegradation of Plastic Materials for packaging) and ISO 14021 (Environmental labels and declarations - Self-declared environmental claims).
• Mermaid Diagram:

  stateDiagram-v2
      state "Intact Formulation" as Intact
      state "Tamper/Exposure Detected" as Detected
      state "Stage 1: Masking Triggered" as Masking
      state "Stage 2: Quenching Triggered" as Quenching
      state "Deactivated Formulation" as Deactivated
  
      [*] --> Intact
      Intact --> Detected: Frangible Seal Breach OR O2 Exposure
      Detected --> Masking: Release Bitterant & Color Indicator
      Masking --> Quenching: Release Chemical Scavenger (PEI)
      Quenching --> Deactivated: Nicotine Bound, Pyruvic Acid Quenched
      Deactivated --> [*]
      note on Detected: Formulation (Nicotine Pyruvate)
      note on Masking: Visually marked, Unpalatable
      note on Quenching: Irreversible nicotine binding, non-aerosolizable
  

---

Derivatives of Core Device Claim: An electronic cigarette for generating an inhalable aerosol comprising a fluid storage compartment, a heater, a nicotine salt liquid formulation in the compartment (where the acid has a vapor pressure >20 mmHg at 200° C.), a battery, and a mouthpiece.

Derivative 3.1: Material & Component Substitution - Ceramic-Graphene-Solid-State Device

• Enabling Description: An electronic cigarette device featuring a fluid storage compartment and an integrated aerosol pathway constructed entirely from biocompatible zirconia-toughened alumina (ZTA) ceramic, providing superior chemical inertness, thermal shock resistance, and easy cleaning. The heater comprises a graphene-based resistive heating element (e.g., a patterned graphene film on a ceramic substrate) capable of ultra-rapid heating (<100ms to 200°C) and maintaining highly precise temperature control (±1°C). The power source is a **solid-state lithium-ion battery** (e.g., a Li-garnet type, such as LLZO) offering enhanced safety (non-flammable electrolyte), higher energy density, and faster charging cycles compared to conventional liquid-electrolyte batteries. The mouthpiece is molded from a medical-grade, **antimicrobial thermoplastic elastomer (TPE)** with embedded silver ions (Ag+), designed for ergonomic comfort and reduced microbial contamination. The device contains a nicotine salt formulation (e.g., **nicotine succinate**, where succinic acid has a vapor pressure >20 mmHg at 200°C) that benefits from the ZTA's inertness, preventing leaching or degradation of the formulation due to device materials.
• Combination Prior Art: This derivative combines US12156533 with ISO 13485 (Medical devices - Quality management systems) and IEEE 1725 (Rechargeable Batteries for Portable Electronic Devices - Safety Standard).
• Mermaid Diagram:

  graph LR
      A[Solid-State Li-Ion Battery] -- Powers --> B[Graphene Heater (Rapid, Precise Temp)];
      B -- Heats --> C[ZTA Ceramic Fluid Compartment];
      C -- Contains --> D[Nicotine Salt Formulation (Succinic Acid VP>20mmHg@200C)];
      C -- Routes Aerosol --> E[ZTA Ceramic Aerosol Pathway];
      E --> F[Antimicrobial TPE Mouthpiece];
      F -- User Inhales --> G[Aerosol];
  

Derivative 3.2: Operational Parameter Expansion - Modular, Ruggedized, Multi-Atmosphere Device

• Enabling Description: An electronic cigarette device designed as a highly modular and ruggedized system for diverse and extreme operational environments (e.g., military field use, scientific expedition, or disaster relief).
  • Modular Fluid & Heater System: The device features interchangeable fluid storage compartments, ranging from micro-cartridges (0.1 mL) for precise single-dose delivery to macro-reservoirs (100 mL) for extended multi-user or industrial applications. The heater is a reconfigurable, multi-zone heating array (e.g., MEMS-based micro-heaters) capable of generating complex temperature profiles (100°C to 300°C) and adapting to different formulation viscosities or aerosolization requirements. The nicotine salt formulation (e.g., nicotine salicylate, with salicylic acid VP >20 mmHg at 200°C) is specifically pre-calibrated for each module type and stored with corresponding operational profiles.
  • Extreme Environmental Endurance: The device housing is constructed from a hardened aerospace-grade titanium alloy (Ti-6Al-4V) with military-spec sealing (IP69K rating), providing complete protection against dust, high-pressure water jets, and extreme temperatures (-50°C to +80°C ambient). All internal electronic components are hermetically sealed and conformally coated against moisture, corrosive agents, and electromagnetic interference. The device maintains consistent aerosol generation in varying atmospheric pressures (from 0.2 atm to 5 atm) through an integrated, passive pressure-equalization system utilizing hydrophobic microporous membranes and active thermal management. The battery module is also ruggedized and swappable, supporting high-capacity, low-temperature tolerant cells.
• Combination Prior Art: This derivative combines US12156533 with MIL-STD-810H (Environmental Engineering Considerations and Laboratory Tests for material endurance), IEC 60529 (Degrees of protection provided by enclosures - IP Code), and Open Compute Project (OCP) principles for modular hardware design.
• Mermaid Diagram:

  graph TD
      A[Ruggedized Housing (Ti-6Al-4V, IP69K)] --> B{Swappable Fluid Compartments};
      B -- Micro-cartridge (0.1mL) --> B1[Nicotine Salicylate Formulation];
      B -- Macro-reservoir (100mL) --> B2[Nicotine Salicylate Formulation];
      A --> C{Reconfigurable Multi-Zone Heater Array};
      C -- 100-300C --> D[Adaptive Temp. & Viscosity Profiles];
      A --> E{Ruggedized Swappable Battery Module};
      A --> F[Hermetically Sealed Electronics];
      A --> G[Passive Pressure-Equalization System];
      G --> H[Multi-Atmosphere Operation (0.2-5 atm)];
  

Derivative 3.3: Cross-Domain Application - Precision Odorant Delivery for Gas Leak Detection Training

• Enabling Description: An aerosol-generating device repurposed as a precision odorant delivery system for training gas leak detection personnel. The fluid storage compartment holds a solution of a non-toxic, non-flammable calibration odorant (e.g., a sulfur-containing compound like tert-butylmercaptan) complexed with a low-volatility, non-reactive organic acid (e.g., lauric acid, characterized by a vapor pressure >20 mmHg at 200°C) in a carrier blend of medical-grade propylene glycol and water. The device's heater and atomizer are precisely calibrated to generate minute, repeatable concentrations of the odorant aerosol (e.g., parts-per-billion range) at varying puff durations and frequencies. The "mouthpiece" is replaced by a standardized aerosol output nozzle designed for controlled dispersion into a training environment. This system allows for realistic and safe simulation of gas leak scenarios, enabling personnel to train with chemical detectors or olfactory senses. The device includes a secure lockout mechanism to prevent unintended use.
• Combination Prior Art: This derivative combines US12156533 with ISO 17776 (Petroleum and natural gas industries - Offshore production installations - Guidelines on tools and techniques for hazard identification and risk assessment) and OSHA regulations for confined space entry and hazardous material training.
• Mermaid Diagram:

  flowchart TD
      A[Precision Odorant Delivery Device] --> B{Fluid Storage Compartment};
      B -- Contains --> C[Calibration Odorant + Nicotine Laurate Formulation];
      C --> D[Heater & Atomizer (Precision Calibration)];
      D --> E[Standardized Aerosol Output Nozzle];
      E --> F[Training Environment (Simulated Leak)];
      F -- Detects --> G[Personnel/Detectors];
      A --> H[Secure Lockout Mechanism];
  

Derivative 3.4: Integration with Emerging Tech - AI-Predictive Maintenance & Blockchain-Audited Device

• Enabling Description: An electronic cigarette device incorporating AI-driven predictive maintenance and blockchain-audited lifecycle management. The device features an array of embedded IoT sensors (e.g., micro-accelerometers for drop/impact detection, internal optical sensors for wick degradation, thermistors for battery health, and current/voltage sensors for heater impedance changes). An onboard edge AI processor analyzes this sensor data in real-time, predicting component failures (e.g., heater coil burnout, battery degradation, atomizer clogging) before they occur. The AI triggers proactive user alerts (via a companion app) for maintenance or replacement and automatically adjusts operational parameters (e.g., reduced power to a failing heater) to extend device life safely. The nicotine salt formulation (e.g., nicotine levulinate, with levulinic acid VP >20 mmHg at 200°C) performance is continuously optimized. Furthermore, each device has a unique cryptographic identity stored on a permissioned blockchain ledger (e.g., Hyperledger Fabric). This ledger immutably records manufacturing data, firmware updates, certified repairs, and verified operational logs (e.g., total puffs, battery cycles). When the device connects to a charging station or syncs with its companion app, it authenticates its identity against the blockchain, verifying its integrity and preventing the use of counterfeit hardware. This also facilitates efficient, verifiable product recalls and warranty management.
• Combination Prior Art: This derivative combines US12156533 with ISO/IEC 30141 (Internet of Things - Reference Architecture), NIST SP 800-193 (Platform Firmware Resiliency Guidelines), and IEEE P2970 (Standard for the Framework of Distributed Ledger Technology for IoT).
• Mermaid Diagram:

  stateDiagram-v2
      state "Operational" as Active
      state "Predictive Maintenance" as PredMaint {
          direction LR
          Sensors --> EdgeAI: Real-time Data (Wick, Battery, Heater)
          EdgeAI --> EdgeAI: Analyze & Predict Failures
          EdgeAI --> UserApp: Proactive Alerts (Maintenance/Replace)
          EdgeAI --> DeviceControl: Adjust Parameters (Extend Life Safely)
      }
      state "Blockchain Lifecycle Audit" as BlockchainAudit {
          direction LR
          DeviceID --> BlockchainLedger: Mfg, Firmware, Repairs, Logs
          DeviceAuth --> BlockchainLedger: Authenticate Identity
          BlockchainLedger --> AuthenticatedDevice: Verify Integrity (Counterfeit Prevention)
          AuthenticatedDevice --> RecallMgmt: Efficient & Verifiable Recalls
      }
      [*] --> Active
      Active --> PredMaint: Continuous Monitoring
      Active --> BlockchainAudit: Periodic Authentication/Logging
  

Derivative 3.5: The "Inverse" or Failure Mode - Auto-Deactivating, Component-Separating Device

• Enabling Description: An electronic cigarette device designed for user-assisted auto-deactivation and component separation for enhanced recycling.
  • Timed Deactivation & Data Wipe: The device is programmed to reach a pre-defined end-of-life (EOL) (e.g., after 5,000 puffs or 2 years, indicated by an LED display). Upon reaching EOL, the device initiates a permanent software lockout of the heating function and performs a secure wipe of all stored user data (e.g., puff history, personalized settings) in compliance with data privacy regulations. This renders the device non-functional and protects user information. The fluid storage compartment still contains the nicotine salt formulation (e.g., nicotine pyruvate, where pyruvic acid has a vapor pressure >20 mmHg at 200°C) but it cannot be aerosolized.
  • Thermo-Responsive Self-Separation: The device housing and internal structural components are constructed using various polymers with different glass transition temperatures (Tg) and specific thermal release adhesives. At EOL, the device guides the user through a simple, localized heating process (e.g., using a low-power internal resistive element at 120-150°C for 30 seconds, or by exposure to hot water) which selectively weakens or releases specific adhesive bonds. This allows the user to easily separate the device into its core material streams (e.g., plastics, battery, metal heater element, glass/ceramic fluid compartment) for efficient, mixed-material recycling. The mouthpiece, made of silicone, also detaches cleanly. Any residual formulation in the separated cartridge can then be neutralized using a provided household reagent.
• Combination Prior Art: This derivative combines US12156533 with WEEE Directive (Waste Electrical and Electronic Equipment) for electronic waste management, IEC 62368 (Safety of multimedia equipment), and ISO 14001 (Environmental management systems).
• Mermaid Diagram:

  graph TD
      A[E-Cigarette Device] --> B{EOL Triggered (e.g., 5k Puffs/2 Yrs)};
      B --> C[Software Lockout (Heating Function)];
      B --> D[Secure User Data Wipe];
      C & D --> E[Non-Functional Device];
      E --> F{User Initiates Component Separation};
      F -- Localized Heating/Water Exposure --> G[Thermo-Responsive Adhesives Weaken];
      G --> H[Separate Material Streams (Plastics, Battery, Metals)];
      H --> I[Recycling Facilities];
      H --> J[Formulation Cartridge (Nicotine Pyruvate)];
      J --> K[Household Neutralization of Residual Formulation];
      K --> L[Safe Disposal];
  

---